Attorney General Bridget Hill announced a settlement with Sanofi-Aventis U.S. LLC (Sanofi), which guarantees that Wyoming ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly ...

The closer you get to the final stage of diabetes nephropathy, called kidney failure, or end-stage renal disease (ESRD), the more likely you will need specific medications or procedures to manage your ...

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...

Research published in "The Lancet Regional Health – Europe" found that sugary drinks, ready-to-eat meals, savory snacks, and processed meats were more closely linked to Type 2 diabetes than other ...

Although HbA1c testing remains the gold standard for glucose monitoring in type 1 and type 2 diabetes, limitations include ...

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Novo Nordisk's decision to stop insulin pen production poses a serious challenge to diabetes care in South Africa, where ...